Biotechnology Hub

Physical pipettes are giving way to acoustic liquid handlers driven by reinforcement learning agents, collapsing the lead discovery pipeline from 4 years to 14 days.

Double-strand breaks and random indels have plagued clinical CRISPR. The latest generation of engineered pegRNA architectures eliminates off-target cleavage entirely.

Spider silk, aerospace composites, and performance textiles are being grown inside stainless steel bioreactors at costs rivaling synthetic plastics.

An exclusive breakdown of global life science venture allocations, private valuations, and the reopening of the public biotech IPO window.

Without a single cow, bio-reactors are delivering authentic cheese, butter, and milk proteins while slashing agricultural land and water consumption by 92%.

When we possess the technology to eliminate cardiovascular predisposition and neurodegenerative alleles before embryo implantation, is withholding intervention a form of medical neglect?

Autologous CAR-T costs $450,000 and requires weeks of personalized manufacturing. Off-the-shelf universal donor batches are cutting treatment costs by 85% while shipping in under 48 hours.

Weight loss is no longer the clinical challenge—preserving lean skeletal muscle and metabolic rate is. The clinical pipeline of multi-receptor peptides is redefining obesity pharmacotherapy.

Single-cell RNA sequencing required grinding tissues into liquid suspensions, destroying architectural context. Spatial transcriptomics preserves every cell's native coordinate inside intact biopsies.

Antibiotics are broad-spectrum weapons that decimate beneficial gut flora. Precision CRISPR phages act as biological snipers, hunting down antibiotic resistance genes with surgical specificity.